Artemisinin

Nobel Prize-winning antimalarial with robust efficacy data. Longevity and anticancer research is preclinical but growing.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Artemisinin-based combination therapies (ACTs) are WHO first-line treatment for P. falciparum malaria. Mechanism involves endoperoxide bridge activation by iron-rich heme in parasites. Preclinical anticancer activity via iron-dependent oxidative damage and ferroptosis is under active investigation.

• WHO-recommended first-line antimalarial treatment
• Novel iron-dependent mechanism of action
• Active preclinical anticancer research program

Malaria: weight-based dosing in combination regimens (e.g., artemether-lumefantrine). Not for self-dosing.

• Nausea
• Dizziness
• Neutropenia (rare with short courses)
• QT prolongation (some derivatives)

Should only be used as part of combination therapy for malaria to prevent resistance. Drug interactions with CYP enzymes. Not a standalone anticancer treatment.

Antimalarial evidence is world-class. Anticancer and longevity applications remain preclinical.

• Immunity75
• Longevity25